# Scientific Skeptic Evaluation
## Foundational Weaknesses
**Causal Direction Ambiguity**: The hypothesis assumes gut bacteria → peripheral inflammation → neuroinflammation, but the reverse causality is equally plausible. Alpha-synuclein pathology may originate in the enteric nervous system, propagate via the vagus nerve, and cause gut barrier dysfunction as a *consequence* (Sampson et al., 2016). The proposed inflammatory cycle may be downstream, not upstream, of alpha-synuclein aggregation.
**NLRP3 Specificity Unjustified**: The hypothesis fixates on NLRP3 without excluding other inflammasomes (NLRP1, AIM2, NLRC4). MCC950, commonly used as a "selective" NLRP3 inhibitor, has documented off-target effects at higher concentrations. Moreover, AIM2 deficiency paradoxically *increases* neurodegeneration in some models—suggesting inflammasome activation may be partially neuroprotective rather than purely deleterious.
## Missing Critical Evidence
1. **No human clinical data** linking gut-derived NLRP3 activation to Parkinson's progression—the cited literature is almost exclusively preclinical
2. **Mechanistic pathway**: How exactly do peripheral macrophage signals reach and